HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
Sample Articles
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
PRODUCTS
CONTACT US
The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1621
In Brief: Hypertension with Erenumab (Aimovig)
 Select a term to see related articles  Aimovig   Ajovy   Drug Safety   Emgality   eptinezumab   erenumab   fremanezumab   glacanezumab   Hypertension   Migraine   Vyepti 

The once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) receptor antagonist erenumab-aooe (Aimovig) was approved by the FDA in 2018 for preventive treatment of migraine in adults.1 Now the FDA has added a new warning to its labeling about a risk of new-onset hypertension and worsening of preexisting hypertension associated with use of the drug. CGRP is a potent microvascular vasodilator; blocking or deleting it has produced hypertensive effects in animals.2

A retrospective analysis of postmarketing reports submitted to the FDA Adverse Events Reporting System identified 61 cases of elevated blood pressure associated with erenumab use, of which 41 were considered serious and 7 required hospitalization. Many cases occurred in patients with preexisting hypertension or risk factors for hypertension such as age ≥65 years, dyslipidemia, and diabetes. The median reported increases in systolic and diastolic blood pressure were 39 and 28 mm Hg, respectively. Most cases were associated with the first or second dose of erenumab. Of the 44 cases in which time to onset was reported, 28 occurred ≤7 days after the most recent dose. Hypertension was reported both with and without concurrent triptan use.3 One Medical Letter reviewer reported a case of hypertension that persisted for >3 months after stopping erenumab, even with use of antihypertensive therapy.

In contrast, a retrospective analysis of four randomized, double-blind, placebo-controlled clinical trials including 2443 patients did not finnd an association between erenumab use and hypertension or vascular events; these trials excluded patients who had experienced a serious cardiovascular event in the previous 12 months.4

Eptinezumab-jjmr (Vyepti), fremanezumab-vfrm (Aiovy), and galcanezumab-gnlm (Emgality), the other CGRP antagonists approved by the FDA for migraine prevention, block CGRP itself rather than its receptors. Their labels do not contain warnings about a risk of hypertension. Patients with significant cardiovascular risk factors were also excluded from clinical trials of these agents.5

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.

© 2021 The Medical Letter, Inc.